Lisheng Pharmaceuticals (002393.SZ): The chemical raw material aprimidine passed the marketing license application

Zhitong Finance App News, Lisheng Pharmaceutical (002393.SZ) issued an announcement. Recently, the company received the Apomistate API (hereinafter referred to as the “API”) and the “Chemical Ingredient Marketing Application Approval Notice” (Notice Number: 2024YS00982) issued by the State Drug Administration. The API passed the marketing application for domestically produced chemical raw materials.

This variety mainly suppresses inflammation by inhibiting the synthesis of phosphodiesterase 4 and increasing the content of cyclic adenosine phosphate in cells. Clinically used to treat adult patients with moderate to severe plaque psoriasis who meet the indications for light therapy or systematic treatment.